Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Post by ForexWhaleon Nov 06, 2018 9:14am
115 Views
Post# 28929468

Something interesting is happening for sure

Something interesting is happening for sureWhen I checked F2G Pharma adviosry board which is another well established anti-fungal R & D company in UK,  Dr. John Perfect and Prof David Denning both are mentioned as advisors.

https://www.f2g.com/advisors/

Below link is also useful to judge ICO potential.

https://www.f2g.com/antifungal-market/

I think with the phase 1 results much better than anticipated and compared to competition, something is brewing up with regard to these advisory board hirings and a possible JV might be in the pipeline. Its inevitable that they will combine forces with established anti-fungal R & D companies to fast track development of ICO-019.
<< Previous
Bullboard Posts
Next >>